🔗 Share this article The Global Health Body Issues Concern Over Severe Scarcity of Obesity Injections Under 10% of patients who could benefit from obesity jabs like Wegovy have access to them, warns the global health agency as it releases its inaugural recommendations on the therapies. Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for more widespread and fairer access to GLP-1 medication. Per projections, more than two billion are projected to be living with obesity by 2030 without intervention. "Our latest guidelines acknowledges that obesity is a lifelong illness that can be addressed with comprehensive and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and logistical bottlenecks are major barriers to broad availability to the treatments that can assist patients in reducing substantial body mass, explains the organization. Weight-Loss Drug Scarcity Even in the present most favorable outlook, the manufacturing of these medications could only cover around 100 million people – fewer than 10% of the global need, according to the WHO. The recommendation urges nations and manufacturers to widen access, by measures such as voluntary licensing. A patent on semaglutide – the main component of the drug Wegovy – is due to expire in a number of nations in 2026. How Weight-Loss Injections Operate The injections replicate a natural hormone to delay gastric emptying, suppress the appetite and enhance the sense of being full so people consume fewer calories. Patients typically see weight reduction within a few weeks of commencing the once-weekly jabs. Studies suggests users may regain a significant portion within a year of discontinuing the drug, as their typical appetite return. Being carrying excess weight raises your likelihood for experiencing medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers. Excess weight concerns individuals in all nations and was linked to over three and a half million fatalities worldwide in 2024, as per the WHO.
Under 10% of patients who could benefit from obesity jabs like Wegovy have access to them, warns the global health agency as it releases its inaugural recommendations on the therapies. Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for more widespread and fairer access to GLP-1 medication. Per projections, more than two billion are projected to be living with obesity by 2030 without intervention. "Our latest guidelines acknowledges that obesity is a lifelong illness that can be addressed with comprehensive and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and logistical bottlenecks are major barriers to broad availability to the treatments that can assist patients in reducing substantial body mass, explains the organization. Weight-Loss Drug Scarcity Even in the present most favorable outlook, the manufacturing of these medications could only cover around 100 million people – fewer than 10% of the global need, according to the WHO. The recommendation urges nations and manufacturers to widen access, by measures such as voluntary licensing. A patent on semaglutide – the main component of the drug Wegovy – is due to expire in a number of nations in 2026. How Weight-Loss Injections Operate The injections replicate a natural hormone to delay gastric emptying, suppress the appetite and enhance the sense of being full so people consume fewer calories. Patients typically see weight reduction within a few weeks of commencing the once-weekly jabs. Studies suggests users may regain a significant portion within a year of discontinuing the drug, as their typical appetite return. Being carrying excess weight raises your likelihood for experiencing medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers. Excess weight concerns individuals in all nations and was linked to over three and a half million fatalities worldwide in 2024, as per the WHO.